Clinical Trials Directory

Trials / Completed

CompletedNCT00581295

Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients

Status
Completed
Phase
Study type
Observational
Enrollment
93 (actual)
Sponsor
University of California, Irvine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Trauma remains the leading cause of death and disability for Americans age 1-44. Trauma can cause internal bleeding, and this bleeding is often hard to detect without sophisticate tests that take time to complete and analyze. In addition, internal bleeding, including bleeding into the lung and chest cavity, as well as other blood loss, happens in many critically ill patients. For example, for hemorrhage, it is very difficult to detect active hemorrhage and to determine optimal rates of fluid and blood resuscitation. Diffuse optical spectroscopy has the potential to accurately assess adequacy of tissue perfusion, oxygenation, tissue oxygen extraction, and cytochrome oxidation states that may be critical to optimal treatment, end- organ preservation, and survival.

Detailed description

The research' want to monitor tissue perfusion and indicators of tissue damage and viability in critically ill patients by using DOS. Non-invasive Optical Techniques DOS,near-infrared diffuse optical spectroscopy (NIR-DOS. NIR-DOS provides functional physiologic tissue/organ information without ionizing radiation and without withdrawing any blood, in a cost-effective and rapid manner. The application of frequency-domain photon migration analysis (FDPM) to NIRS allows independent measurements of tissue absorption and scattering properties at depths of 1 cm or more below the skin surface. Such capabilities will improve early diagnosis, detection, optimization of therapy, assessment of adequacy of resuscitation, and alteration in management plans for all of these critical conditions.

Conditions

Interventions

TypeNameDescription
DEVICEDiffuse optical spectroscopyDiffuse optical spectroscopy measurment

Timeline

Start date
2007-03-01
Primary completion
2011-04-01
Completion
2011-04-01
First posted
2007-12-27
Last updated
2022-11-01

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00581295. Inclusion in this directory is not an endorsement.